Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy

NCT03080883 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT03080883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03080883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 3
Overall status
Completed
Start date
July 14, 2017
Completion date
May 9, 2025
Enrollment
370 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral vein thrombosis, deep vein thrombosis, hematopoietic and lymphoid cell neoplasm, malignant solid neoplasm, metastatic malignant solid neoplasm, pulmonary embolism, splanchnic vein thrombosis